Immunotherapy has transformed cancer treatment, but its effectiveness varies widely among patients, and some who initially respond eventually develop resistance. Identifying which patients are most likely to benefit remains a significant clinical challenge. Now, researchers have developed a liquid biopsy that could provide a simpler, non-invasive method to forecast immunotherapy responses in patients with advanced lung cancer.
The new approach analyzes circulating tumor DNA (ctDNA) in the blood to detect specific genetic alterations, such as tumor mutational burden and microsatellite instability, which are known predictors of immunotherapy efficacy. Unlike traditional tissue biopsies, which are invasive and often difficult to obtain in advanced disease, a simple blood draw can provide real-time insights into the tumor's genomic profile. This allows clinicians to make more informed treatment decisions, potentially sparing patients from ineffective therapies and their associated side effects.
Beyond its clinical utility, this liquid biopsy could have significant implications for the biopharmaceutical industry. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which are developing innovative immunotherapies, could leverage this tool to screen and stratify patients in clinical trials. By enriching trial populations with likely responders, these companies may enhance the efficiency of their studies, reduce costs, and accelerate the path to regulatory approval.
The development addresses a critical need in oncology, as immunotherapy response rates remain low—often below 30% in certain cancers—and the ability to predict who will benefit is paramount. The liquid biopsy's simplicity and repeatability also enable longitudinal monitoring, allowing clinicians to track changes in ctDNA over time and detect emerging resistance early, potentially guiding adjustments in therapy.
Researchers are optimistic that this tool will not only improve patient outcomes but also facilitate the development of combination strategies and personalized treatment plans. As the field of precision oncology advances, such non-invasive biomarkers are becoming increasingly essential.
For more information on the latest developments in biotech and life sciences, visit BioMedWire.
